Vertex Pharmaceuticals shares sank Thursday after the company reported mixed results in a Phase 2 drug trial to treat ...

The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' next-generation treatment for a rare and ...

Vertex的药物suzetrigine被誉为一项科学突破，因为它阻断了一种有助于控制人体神经元活动的钠通道，在不进入大脑的情况下治疗疼痛。这使得它比阿片类药物更不容易上瘾，在截至2024年6月的一年中，阿片类药物导致约7万人因过量服用而死亡。如果获 ...

The Food and Drug Administration signed off on Vertex Pharmaceuticals' next-generation triple drug for cystic fibrosis late ...

这一消息直接来自Vertex Pharmaceuticals Incorporated，报告的签署人是公司执行副总裁兼首席法务官Jonathan Biller。FDA对ALYFTREK的批准是Vertex Pharmaceuticals的一个重要进展，可能会加强公司在囊性纤维化治疗领域的产品组合。

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced results from its Phase 2 study of suzetrigine for painful ...

CNBC’s Jim Cramer delivers his daily Mad Dash. Drones Banned in New Jersey Over 'Imminent Security Threat' Finnair New A350 - ...

该股的盘前表现反映了不确定性，下跌12%。考虑到对公司正在进行的糖尿病周围神经病变（DPN）三期试验的潜在影响，这一反应可能被认为是适度的。最初，分析师认为LSR试验结果对DPN试验的影响有限，暗示可能存在买入机会。然而，在更详细地回顾了过去的DPN试验后，伯恩斯坦决定保持谨慎态度。

Needham analyst Joseph Stringer has maintained their neutral stance on VRTX stock, giving a Hold rating yesterday.Pick the best stocks and ...

Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity” third ...

正如预期的那样，今年制药公司对并购仍有兴趣，但相较于大型并购，制药公司更倾向于小额交易。迄今为止宣布的最大额的一笔交易是Novo Holdings拟以165亿美元收购CDMO公司Catalent。

Vertex Pharmaceuticals (VRTX) said Friday the U.S. Food and Drug Administration expanded its approval of a cystic fibrosis treatment, ...